Guangshengtang hepatitis B treatment global innovative drug GST-HG141 was clinically approved

Viral hepatitis B (hepatitis B) is an infectious disease caused by hepatitis B virus (HBV) mainly from helitosis and can cause multi-organ damageAccording to the World Health Organization's Global Hepatitis Report 2017, there are approximately 257 million people living with HBV worldwideIt is estimated that there are about 86 million people infected with HEPATItIs virus in China, of whom about 28 million are chronic hepatitis B patientsat present, hepatitis B treatment drugs are mainly divided into two categories: interferon and nucleotide (acid) analogues, can not effectively remove hepatitis B virus to achieve functional cure for the purpose of discontinuing drugsTo date, no drugs or programmes have been approved worldwide for hepatitis B treatmentGST-HG141 is a new type 1 new anti-hepatitis B virus class 1 drug with a new target mechanism that is different from existing listed nucleotide (acid) drugsThe project is one of the most important components of the Guangshengtang functional cure hepatitis B "peak plan", there is no target drug approved to market in the world, preclinical research data show that GST-HG141 safety, excellent effectiveness, is expected to become the best-in-Class project in this fieldpreclinical results show that GST-HG141 has the following characteristics:1, for hepatitis B virus replication of several key links play a role, both strongly inhibit the nuclear shell assembly of hepatitis B virus, while inhibiting HBV in the nuclei surface of the liver cell, destroy the hepatitis B virus cccDNA (covalent closed ring DNA) virus pool establishment, reduce the hepatitis B virus library reserve, so in multiple doses In the group, thelevels of HBV-DNA (hepatitis B virus DNA), HBeAg (hepatitis B virus E antigen) were significantly reduced, and in comparison with tinofovir and in joint trials, GST-HG141 showed a strong direct antiviral effect from nucleoside (acid) analogues, and had synergies with the combination with tenofovir3, hepatitis B core protein inhibitor GST-HG141 and the company in the research (generation) hepatitis B surface antigen inhibitor GST-HG131 (First-in-Class) or (second-generation) hepatitis B surface antigen inhibitor GST-HG121 and traditional nucleoside (acid) similar drugs are in the preclinical exploration stage;Guangshengtang said that with the GST-HG131, GST-HG121 project this year and next year in China's IND (clinical registration) application and promotion, the company plans to start in 2020 around the world for functional treatment of hepatitis B clinical trials and drug combination program researchAt the same time, will actively carry out the United States FDA and other international clinical registration and declaration matters, and choose the opportunity to only for overseas interests alone financing and seeking overseas cooperative development partnerscurrently, Guangshengtang has applied for PCT international patents, including GST-HG141 core compounds, and plans to enter more than 20 countries and regions, including China, the United States, Japan, and Europe.